Rifaximin for the treatment of acute infectious diarrhea

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 4, 2011, Pages 227-235

  Hong, Kyoung Sup ^a   Kim, Joo Sung ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Acute infectious diarrhea; Rifaximin; Travelers' diarrhea

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; CYTOCHROME P450; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN;

ACUTE INFECTIOUS DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; CAMPYLOBACTERIOSIS; CHEMOPROPHYLAXIS; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE STUDY; DISEASE DURATION; DRUG BIOAVAILABILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTIOUS DIARRHEA; MEXICO; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOUTH KOREA; TRAVELLER DIARRHEA;

EID: 79959553828     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11398734     Document Type: Review

References (61)

1. Berman A.L. (2007) Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 41: 932–933.
2. Boero M. Berti E. Morgando A. (1990) Treatment of colitis caused by Clostridium difficile: results of an open random study between rifaximin and vancomycin. Microbiol Med 5: 74–77.
3. Camilleri M. Murray J.A. Diarrhea and constipation. In: Ed. Fauci A.S. Braunwald E. Kasper D.L. Hauser S.L. Longo D.L. Jameson J.L. (eds). (2008) Harrison's Principles of Internal Medicine McGraw-Hill: New York.
4. Carter A.O. Borczyk A.A. Carlson J.A. Harvey B. Hockin J.C. Karmali M.A. et al (1987) A Severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 317: 1496–1500.
5. Cho S.H. Shin H.H. Choi Y.H. Park M.S. Lee B.K. (2008) Enteric bacteria isolated from acute diarrheal patients in the Republic of Korea between the year 2004 and 2006. J Microbiol 46: 325–330.
6. Chong Y. Lee K. Park Y.J. Jeon D.S. Lee M.H. Kim M.Y. et al (1998) Korean nationwide surveillance of antimicrobial resistance of bacteria in 1997. Yonsei Med J 39: 569–577.
7. Curry S.R. Marsh J.W. Shutt K.A. Muto C.A. O'leary M.M. Saul M.I. et al (2009) High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 48: 425–429.
8. Darkoh C. Lichtenberger L.M. Ajami N. Dial E.J. Jiang Z.D. Dupont H.L. (2010) Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother 54: 3618–3624.
9. de Leo C. Eftimiadi C. Schito G.C. (1986) Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 12: 979–981.
10. Della Marchina M. Renzi G. Palazzini E. (1988) Infectious diarrhea in the aged: controlled clinical trial of rifaximin. Chemioterapia 7: 336–340.
11. Descombe J.J. Dubourg D. Picard M. Palazzini E. (1994) Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 14: 51–56.
12. Dowling R.H. (1973) The enterohepatic circulation of bile acids as they relate to lipid disorders. J Clin Pathol Suppl (Assoc Clin Pathol) 5: 59–67.
13. Dundas S. Todd W.T. Stewart A.I. Murdoch P.S. Chaudhuri A.K. Hutchinson S.J. (2001) The Central Scotland Escherichia coli O157:H7 outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients. Clin Infect Dis 33: 923–931.
14. Dupont H.L. Ericsson C.D. (1993) Prevention and treatment of traveler's diarrhea. N Engl J Med 328: 1821–1827.
15. Dupont H.L. Ericsson C.D. Mathewson J.J. Palazzini E. Dupont M.W. Jiang Z.D. et al (1998) Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. Digestion 59: 708–714.
16. Dupont H.L. Galler G. Garcia-Torres F. Dupont A.W. Greisinger A. Jiang Z.D. (2010) Travel and travelers' diarrhea in patients with irritable bowel syndrome. Am J Trop Med Hyg 82: 301–305.
17. Dupont H.L. Jiang Z.D. (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and Enterococci. Clin Microbiol Infect 10: 1009–1011.
18. Dupont H.L. Jiang Z.D. Ericsson C.D. Adachi J.A. Mathewson J.J. Dupont M.W. et al (2001) Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 33: 1807–1815.
19. Dupont H.L. Jiang Z.D. Okhuysen P.C. Ericsson C.D. de La Cabada F.J. Ke S. et al (2005) A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 142: 805–812.
20. Eftimiadi C. Deleo C. Schito G. (1984) Treatment of hepatic encephalopathy with L/105, a new non-absorbable rifamycin. Drugs Exp Clin Res 10: 691–696.
21. Ericsson C.D. (2003) Travellers' diarrhoea. Int J Antimicrob Agents 21: 116–124.
22. Garey K.W. Jiang Z.D. Bellard A. Dupont H.L. (2009) Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 43: 91–93.
23. Gillis J.C. Brogden R.N. (1995) Rifaximin. a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 49: 467–484.
24. Gomi H. Jiang Z.D. Adachi J.A. Ashley D. Lowe B. Verenkar M.P. et al (2001) In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions. Antimicrob Agents Chemother 45: 212–216.
25. Guerrant R.L. van Gilder T. Steiner T.S. Thielman N.M. Slutsker L. Tauxe R.V. et al (2001) Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 32: 331–351.
26. Henwood S.Q. de Villiers M.M. Liebenberg W. Lotter A.P. (2000) Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm 26: 403–408.
27. Hoover W.W. Gerlach E.H. Hoban D.J. Eliopoulos G.M. Pfaller M.A. Jones R.N. (1993) Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 16: 111–118.
28. Hong K. Kim Y. Han D. Choi C. Jang B. Park Y. et al (2010) Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: a randomized controlled multicenter study. Gut Liver 4: 357–362.
29. Huang D.B. Dupont H.L. (2005) Rifaximin–a novel antimicrobial for enteric infections. J Infect 50: 97–106.
30. Infante R.M. Ericsson C.D. Jiang Z.D. Ke S. Steffen R. Riopel L. et al (2004) Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2: 135–138.
31. Jiang Z.D. Dupont H.L. (2005) Rifaximin: in vitro and in vivo antibacterial activity–a review. Chemotherapy 51: 67–72.
32. Jiang Z.D. Ke S. Palazzini E. Riopel L. Dupont H. (2000) In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 44: 2205–2206.
33. Johnson S. Schriever C. Galang M. Kelly C.P. Gerding D.N. (2007) Interruption of recurrent clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44: 846–848.
34. Johnson S. Schriever C. Patel U. Patel T. Hecht D.W. Gerding D.N. (2009) Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 15: 290–291.
35. Koo H.L. Dupont H.L. (2010) Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 26: 17–25.
36. Lamanna A. Orsi A. (1984) In vitro activity of rifaximin and rifampicin against some anaerobic bacteria. Chemioterapia 3: 365–367.
37. Lee K. Kim Y.A. Park Y.J. Lee H.S. Kim M.Y. Kim E.C. et al (2004) Increasing prevalence of vancomycin-resistant Enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a Konsar study in 2002. Yonsei Med J 45: 598–608.
38. Luttichau U. Arcangeli P. Sinapi S. (1985) The use of rifaximin in the treatment of acute diarrhoeal enteritis: open study. Panminerva Med 27: 129–132.
39. Martinez-Sandoval F. Ericsson C.D. Jiang Z.D. Okhuysen P.C. Romero J.H. Hernandez N. et al (2010) Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med 17: 111–117.
40. Murray T.S. Baltimore R.S. (2007) Pediatric uses of fluoroquinolone antibiotics. Pediatr Ann 36: 336–342.
41. Musser J.M. (1995) Antimicrobial agent resistance in mycobacteria: molecular genetic insights. Clin Microbiol Rev 8: 496–514.
42. O'Connor J.R. Galang M.A. Sambol S.P. Hecht D.W. Vedantam G. Gerding D.N. et al (2008) Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 52: 2813–2817.
43. Ojetti V. Lauritano E.C. Barbaro F. Migneco A. Ainora M.E. Fontana L. et al (2009) Rifaximin pharmacology and clinical implications. Expert Opin Drug Metab Toxicol 5: 675–682.
44. Okhuysen P.C. Jiang Z.D. Carlin L. Forbes C. Dupont H.L. (2004) Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 99: 1774–1778.
45. Panos G.Z. Betsi G.I. Falagas M.E. (2006) Systematic review: are antibiotics detrimental of beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24: 731–742.
46. Pentikis H.S. Connolly M. Trapnell C.B. Forbes W.P. Bettenhausen D.K. (2007) The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers. Pharmacotherapy 27: 1361–1369.
47. Ripa S. Mignini F. Prenna M. Falcioni E. (1987) In vitro antibacterial activity of rifaximin against Clostridium difficile, Campylobacter jejuni and Yersinia spp. Drugs Exp Clin Res 13: 483–488.
48. Ruiz J. Mensa L. O'callaghan C. Pons M.J. Gonzalez A. Vila J. et al (2007) In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea. Diagn Microbiol Infect Dis 59: 473–475.
49. Salix Pharmaceuticals. Xifaxan (rifaximin) tablet [prescribing information] 2008 Salix Pharmaceuticals: Palo Alto, CA.
50. Sierra J.M. Navia M.M. Vargas M. Urassa H. Schellemberg D. Gascon J. et al (2001 a) In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania. J Antimicrob Chemother 47: 904–905.
51. Sierra J.M. Ruiz J. Navia M.M. Vargas M. Vila J. (2001 b) In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea. Antimicrob Agents Chemother 45: 643–644.
52. Smith K.E. Besser J.M. Hedberg C.W. Leano F.T. Bender J.B. Wicklund J.H. et al (1999) Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992–1998. Investigation Team. N Engl J Med 340: 1525–1532.
53. Soro O. Pesce A. Raggi M. Debbia E.A. Schito G.C. (1997) Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 3: 147–151.
54. Steffen R. Collard F. Tornieporth N. Campbell-Forrester S. Ashley D. Thompson S. et al (1999) Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 281: 811–817.
55. Steffen R. Sack D.A. Riopel L. Jiang Z.D. Sturchler M. Ericsson C.D. et al (2003) Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 98: 1073–1078.
56. Taylor D.N. Bourgeois A.L. Ericsson C.D. Steffen R. Jiang Z.D. Halpern J. et al (2006) A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 74: 1060–1066.
57. Trapnell C.B. Connolly M. Pentikis H. Forbes W.P. Bettenhausen D.K. (2007) Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 41: 222–228.
58. Vila J. Vargas M. Ruiz J. Espasa M. Pujol M. Corachan M. et al (2001) Susceptibility patterns of enteroaggregative Escherichia coliassociated with traveller's diarrhoea: emergence of quinolone resistance. J Med Microbiol 50: 996–1000.
59. Viscomi G. Campana M. Barbanti M. Grepioni F. Polito M. Confortini D. et al (2008) Crystal forms of rifaximin and their effect on pharmaceutical properties. Cryst Eng Comm 10: 1074–1081.
60. Williams D.L. Spring L. Collins L. Miller L.P. Heifets L.B. Gangadharam P.R. et al (1998) Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 42: 1853–1857.
61. Yang J.R. Wu H.S. Chiang C.S. Mu J.J. (2008) Pediatric Campylobacteriosis in Northern Taiwan from 2003 to 2005. BMC Infect Dis 8: 151–151.